RuiYi is focused on the discovery and development of novel antibodies with
upsized potential that represent (1) first in class antibody therapeutics to GPCR
targets validated with small molecules yet never successfully drugged and (2)
best in class antibody therapeutics to validated targets for unique markets,
including emerging markets, with significant medical need. RuiYi is developing
biologic therapeutics for rheumatoid arthritis, metabolic disease, fibrosis and NASH.